LONDON, Sept. 20, 2021 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma), the multinational generic
pharmaceutical company, announces the signing of an exclusive US
license agreement with FAES Farma S.A. to commercialise
Bilastine tablets, a non-sedating second generation antihistamine
molecule for the treatment of allergic rhinitis and urticaria.
Under the terms of the agreement, Hikma will be responsible for
obtaining regulatory approval of Bilastine by the US Food and Drug
Administration (FDA) and for the commercialisation of the product
in the US following approval. Hikma will provide FAES with an
upfront payment, regulatory approval and commercial milestone
payments as well as royalties. The agreement builds upon Hikma and
FAES Farma's existing partnership on Bilastine in the Middle East and North Africa, where Hikma is the exclusive
licensee for Bilastine in 15 countries.
"We are pleased to form this partnership with FAES Farma for
Bilastine, which builds on our growing position in the allergy
market and further advances our objective of strengthening our
specialty business in the US," said Brian
Hoffmann, President of Hikma Generics. "Since its first
launch in Europe in 2011,
Bilastine has been successfully commercialised as a leading allergy
brand in more than 100 countries. By introducing Bilastine in the
US, Hikma is further solidifying its presence in the allergy
market, and we will leverage our existing salesforce promoting our
specialty portfolio, including our partnership with Eyevance
Pharmaceuticals for the co-promotion of ZERVIATE® and
our forthcoming branded seasonal allergic rhinitis nasal spray
Ryaltris™. We look forward to bringing this new treatment option to
US patients."
About Bilastine
Bilastine is a non-sedating second generation antihistamine
molecule for the treatment of allergic rhinitis and urticaria.
Bilastine is currently approved in more than 120 countries and
achieved more than €290 million in worldwide sales in 2020. If
approved by the FDA, Bilastine would be the first New Chemical
Entity antihistamine approved in the US since 2007.
Enquiries
Hikma Pharmaceuticals
PLC
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/
+44 7776 477050
uk-investors@hikma.uk.com
|
|
|
Steve
Weiss
David
Belian
US Communications and
Public Affairs
|
+1 732 788
8279
+1 848 254
4875
uscommunications@hikma.com
|
|
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hikma-and-faes-farma-enter-into-exclusive-licensing-agreement-for-the-commercialisation-of-bilastine-tablets-in-the-us-301380657.html
SOURCE Hikma Pharmaceuticals USA Inc.